Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency.


Journal

British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323

Informations de publication

Date de publication:
02 2023
Historique:
revised: 29 07 2022
received: 25 02 2022
accepted: 15 08 2022
pubmed: 16 9 2022
medline: 18 1 2023
entrez: 15 9 2022
Statut: ppublish

Résumé

Determining dihydropyrimidine dehydrogenase (DPD) activity by measuring patient's uracil (U) plasma concentration is mandatory before fluoropyrimidine (FP) administration in France. In this study, we aimed to refine the pre-analytical recommendations for determining U and dihydrouracil (UH U and UH Storage of blood samples before centrifugation at room temperature (RT) should not exceed 1 h, whereas cold (+4°C) storage maintains the stability of uracil after 5 hours. For patients correctly double sampled, IOV of U reached 22.4% for U (SD = 17.9%, range = 0-99%). Notably, 17% of them were assigned with a different phenotype (normal or DPD-deficient) based on the analysis of their two samples. For those having at least one non-compliant sample, this percentage increased up to 33.8%. The moment of blood collection did not affect the DPD phenotyping result. Caution should be taken when interpreting U concentrations if the time before centrifugation exceeds 1 hour at RT, since it rises significantly afterwards. Not respecting the pre-analytical conditions for DPD phenotyping increases the risk of DPD status misclassification.

Identifiants

pubmed: 36104927
doi: 10.1111/bcp.15536
pmc: PMC10092089
doi:

Substances chimiques

Dihydrouracil Dehydrogenase (NADP) EC 1.3.1.2
Uracil 56HH86ZVCT
Fluorouracil U3P01618RT

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

762-772

Informations de copyright

© 2022 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

Références

Br J Clin Pharmacol. 2016 Sep;82(3):706-16
pubmed: 27161955
Br J Clin Pharmacol. 2023 Feb;89(2):762-772
pubmed: 36104927
Eur J Clin Pharmacol. 2018 Jun;74(6):737-744
pubmed: 29430582
Eur J Cancer. 2004 May;40(7):939-50
pubmed: 15093568
J Clin Oncol. 1994 Nov;12(11):2248-53
pubmed: 7964939
Br J Pharmacol. 2004 Feb;141(4):616-23
pubmed: 14744810
J Pharm Biomed Anal. 2017 Aug 5;142:125-135
pubmed: 28501750
ESMO Open. 2021 Jun;6(3):100125
pubmed: 33895696
Ann Oncol. 2021 Jun;32(6):810-811
pubmed: 33662499
Clin Transl Sci. 2020 Jul;13(4):761-768
pubmed: 32058656
Clin Pharmacol Ther. 2022 Jul;112(1):62-68
pubmed: 35397172
Pharmacogenomics. 2015;16(11):1277-86
pubmed: 26265346
Clin Biochem. 2015 Sep;48(13-14):915-8
pubmed: 25940841
J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Sep 5;823(2):98-107
pubmed: 16027050
Biomed Chromatogr. 2013 Jan;27(1):7-16
pubmed: 22454320
Br J Cancer. 2017 May 23;116(11):1415-1424
pubmed: 28427087
Bull Cancer. 2019 Sep;106(9):759-775
pubmed: 31253356
Rapid Commun Mass Spectrom. 2008;22(2):224-30
pubmed: 18085512
Cancer Lett. 2007 May 8;249(2):271-82
pubmed: 17064846
Br J Cancer. 2020 Sep;123(5):811-818
pubmed: 32595208
Clin Chem Lab Med. 2022 Jan 21;60(5):e112-e115
pubmed: 35073467
PLoS One. 2021 Apr 8;16(4):e0249797
pubmed: 33831088
Biochim Biophys Acta. 2002 Jul 18;1587(2-3):133-44
pubmed: 12084455
Ther Drug Monit. 2020 Aug;42(4):540-547
pubmed: 32384537
Lancet Oncol. 2015 Dec;16(16):1639-50
pubmed: 26603945
Ther Drug Monit. 2012 Feb;34(1):59-66
pubmed: 22210098
Br J Clin Pharmacol. 2018 Dec;84(12):2761-2769
pubmed: 30047584
Clin Cancer Res. 2006 Sep 15;12(18):5491-5
pubmed: 17000684
J Chromatogr Sci. 2012 Nov-Dec;50(10):877-84
pubmed: 22689904
Ann Oncol. 2022 Aug;33(8):850-852
pubmed: 35525375
Ther Drug Monit. 2020 Apr;42(2):344-345
pubmed: 31855974
Eur J Cancer. 2020 Jan;124:37-46
pubmed: 31715555
Bioanalysis. 2009 Jun;1(3):537-48
pubmed: 21083151
Cancer Chemother Pharmacol. 2021 Dec;88(6):1049-1053
pubmed: 34515833
J Pharm Biomed Anal. 2016 Jul 15;126:75-82
pubmed: 27179185
Pharmacogenomics. 2014 Sep;15(13):1653-66
pubmed: 25410891

Auteurs

Maud Maillard (M)

Laboratoire de Pharmacologie, Institut Claudius Regaud, IUCT-Oncopole et Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Université Paul Sabatier, Toulouse, France.

Manon Launay (M)

Laboratoire de Pharmacologie et Toxicologie, CHU de Saint-Etienne, Saint-Etienne, France.

Bernard Royer (B)

Laboratoire de Pharmacologie Clinique et Toxicologie, CHU Besançon and Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.

Jérôme Guitton (J)

Laboratoire de Pharmacologie Toxicologie, CHU de Lyon, Lyon, France.

Elodie Gautier-Veyret (E)

Laboratoire de Pharmacologie, Pharmacogénétique et Toxicologie, CHU Grenoble-Alpes et Université Grenoble-Alpes, laboratoire HP2, INSERM U1300, Grenoble, France.

Sophie Broutin (S)

Département de Biologie et Pathologie Médicale, Service de Pharmacologie, Gustave Roussy, Villejuif, France.

Camille Tron (C)

Laboratoire de pharmacologie CHU de Rennes, Université de Rennes, CHU de Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S 1085, Rennes, France.

Félicien Le Louedec (F)

Laboratoire de Pharmacologie, Institut Claudius Regaud, IUCT-Oncopole et Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Université Paul Sabatier, Toulouse, France.

Joseph Ciccolini (J)

SMARTc Unit, CRCM Inserm U1068 et Laboratoire de Pharmacocinétique, CHU La Timone, Marseille, France.

Damien Richard (D)

Laboratoire de Pharmacologie et Toxicologie, CHU de Clermont-Ferrand, Clermont-Ferrand, France.

Hugo Alarcan (H)

Service de Biochimie et Biologie Moléculaire, CHRU de Tours, Tours, France.

Vincent Haufroid (V)

Louvain Centre for Toxicology and Applied Pharmacology (LTAP), Clinical and Experimental Research Institute (IREC), Université catholique de Louvain, Brussels, Belgium.
Clinical Chemistry Department, Cliniques Universitaires Saint-Luc, Brussels, Belgium.

Naïma Tafzi (N)

INSERM, Université de Limoge, Service de Pharmacologie et Toxicologie, CHU de Limogess, U1248 IPPRITT, Limoges, France.

Antonin Schmitt (A)

Service Pharmacie, Centre Georges-François Leclerc et INSERM U1231, Université de Bourgogne, Dijon, France.

Marie-Christine Etienne-Grimaldi (MC)

Laboratoire d'Oncopharmacologie, Centre Antoine Lacassagne, Nice, France.

Céline Narjoz (C)

Assistance Publique des Hôpitaux de Paris, Hôpital européen Georges-Pompidou, Service de biochimie, Paris, France.

Fabienne Thomas (F)

Laboratoire de Pharmacologie, Institut Claudius Regaud, IUCT-Oncopole et Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Université Paul Sabatier, Toulouse, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH